Freedom of Information Request Reference: 9949
Date Received: 03/04/2025
Summary:
I am analysing the treatment of dermatological conditions in the UK so how many patients were treated in the last 4 months (December 2024 to March 2025) by the dermatology department with each of the following products: • Abrocitinib • Baricitinib • Dupilumab • Lebrikizumab • Tralokinumab • Upadacitinib • Nemolizumab
I am analysing the treatment of dermatological conditions in the UK so how many patients were treated in the last 4 months (December 2024 to March 2025) by the dermatology department with each of the following products: • Abrocitinib • Baricitinib • Dupilumab • Lebrikizumab • Tralokinumab • Upadacitinib • Nemolizumab
Date of Response: 25/04/2025
View Response: 9949.pdf
View Response: 9949.pdf